Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

⟵ Back to Search Results

Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC

Beigene Study ID

BGB-A317-311

ClinicalTrials.gov ID

NCT03957590

Clinical Drug Trials ID

CTR20190198

Study Overview

Sex: All

Age: 18 Years to 75 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years to 75 Years (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You will be redirected to

Click the link above to continue or CANCEL